Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8762-8769

  Feng, Wen Hai ^a   Kenney, Shannon C ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOMA; VIRUS GENE; VIRUS INFECTION;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; HERPESVIRUS 4, HUMAN; HUMANS; LUCIFERASES; MICE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; VALPROIC ACID;

EID: 33749031579     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1006     Document Type: Article

References (54)

1. Kieff E. Epstein-Barr virus and its replication. In: Knipe D, Howley P, editors. Fields virology. 4th ed. Philadelphia (PA): Lippincott-Raven Publishers; 2001. p. 2511-74.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe D, Howley P, editors. Fields virology. 4th ed. Philadelphia (PA): Lippincott-Raven Publishers; 2001. p. 2575-627.
3. Sixby JW, Nedrad JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984;310:1225-30.
4. Li QX Young LS, Niedobitek G, et al. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 1992;356:347-50.
5. Takada K, Shimizu N, Sakuma S, Ono Y. Transactivation of the latent Epstein-Barr virus genome after transfection of the EBV DNA fragment. J Virol 1986;57:1016-22.
6. Feng W-H, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive tumors. Cancer Res 2002;62:1920-6.
7. Feng W-H, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 2004;96:1691-702.
8. Feng W-H, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78:1893-902.
9. Ernberg I, Falk K, Minarovits J, et al. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol 1989;70:2989-3002.
10. Jansson A, Masucci M, Rymo L. Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J Virol 1992;66:62-9.
11. Masucci MG, Contreras-Salazar B, Ragnar E, et al. 5-Azacytidine up-regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol 1989;63:3135-41.
12. Robertson KD, Manns A, Swinnen LJ, Zong JC, Gulley ML, Ambinder RF. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood 1996;88:3129-36.
13. Takacs M, Myohanen S, Altiok E, Minarovits J. Analysis of methylation patterns in the regulatory region of the latent Epstein-Barr virus promoter BCR2 by automated fluorescent genomic sequencing. Biol Chem 1998;379:417-22.
14. Robertson KD. DNA methylation and chromatin-unraveling the tangled web. Oncogene 2002;21:5361-79.
15. Bednarik DP, Cook JA, Pitha PM. Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J 1990;9:1157-64.
16. Boyes J, Bird AP. Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J 1992;11:327-33.
17. Lewis JD, Meehan RR, Henzel WJ, et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell 1992;69:905-14.
18. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 1993;8:1063-7.
19. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 1988;2:1136-43.
20. Moore SM, Cannon JS, Tanhehco Y, Hamzeh F, Ambinder R. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001;45:2082-91.
21. Ben-Sasson SA, Klein G. Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. Int J Cancer 1981;28:131-5.
22. Nonkwelo CB, Long WK. Regulation of Epstein-Barr virus BamHI-H divergent promoter by DNA methylation. Virology 1993;197:205-15.
23. Bhende PM, Kenney SC. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 2004;36:1099-104.
24. Kramer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003;22:3411-20.
25. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-41.
26. Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem 2003;278:27586-92.
27. Kuntz-Simon G, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication. J Gen Virol 1995;76:1409-15.
28. Shaw EN, Arbiser JL, Offermann MK. Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells. AIDS 2000;14:899-902.
29. Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005;105:4028-34.
30. Feederle R, Kost M, Baumann M, et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000;19:3080-9.
31. Adamson AL, Kenney SC. Rescue of the Epstein-Barr virus BZLF1 mutant, Z (S186A), early gene activation defect by the BRLF1 gene product. Virology 1998;251:187-97.
32. + immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med 2005;201:349-60.
33. + T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus Infection. J Exp Med 2002;195:893-905.
34. Countryman J, Miller G. Activation of expression of latent Epstein-Barr virus after gene transfer with a small cloned fragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 1985;82:4085-9.
35. Adamson AL, Darr D, Holley-Guthrie E, et al. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 2000;74:1224-33.
36. Borras AM, Strominger JL, Speck SH. Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. J Virol 1996;70:3894-901.
37. Liu S, Liu P, Borras A, Chatila T, Speck SH. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J 1997;16:143-53.
38. Livingstone C, Patel G, Jones N. ATF-2 contains a phosphorylation- dependent transcriptional activation domain. EMBO J 1995;14:1785-97.
39. Wang YC, Huang JM, Montalvo EA. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 1997;227:323-30.
40. Kraus RJ, Perrigoue JG, Mertz JE. ZEB Negatively Regulates the Lytic-Switch BZLF1 Gene Promoter of Epstein-Barr Virus. J Virol 2003;77:199-207.
41. Robertson KD, Ambinder RF. Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood 1997;90:4480-4.
42. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
43. Kadonaga J. Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell 1998;92:307-13.
44. Pazin M, Kadonaga J. What's up and down with histone deacetylation and transcription? Cell 1997;89:325-8.
45. Murphy JC, Fischle W, Verdin E, Sinclair JH. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J 2002;21:1112-20.
46. Jenkins PJ, Binne UK, Farrell J. Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol 2000;74:710-20.
47. Bryant H, Farrell P. Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J Virol 2002;76:10290-8.
48. Yuan PX Huang LD, Jiang YM, Gutkind S, Manji K, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001;276:31674-83.
49. Gregoire S, Yang XJ. Association with class IIa histone deacetylases up-regulates the sumoylation of MEF2 transcription factors. Mol Cell Biol 2005;25:2273-87.
50. Kato Y, Zhao M, Morikawa A, et al. Big mitogen-activated kinase regulates multiple members of the MEF2 protein family. J Biol Chem 2000;275:18534-40.
51. Yang CC, Ornatsky OI, McDermott JC, Cruz TF, Prody CA. Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1. Nucleic Acids Res 1998;26:4771-7.
52. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78.
53. Kaisern M, Zavrski I, Sterz J, et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006;91:248-51.
54. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996;334:168-75.